Q1 Earnings Estimate for HOWL Issued By Leerink Partnrs

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Werewolf Therapeutics in a note issued to investors on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics’ Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.51) EPS.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10.

A number of other brokerages have also recently weighed in on HOWL. JMP Securities decreased their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Bank of America decreased their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Finally, Wedbush decreased their price target on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating on the stock in a research note on Friday, May 9th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $8.00.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $1.35 on Friday. The stock has a market cap of $61.74 million, a price-to-earnings ratio of -0.82 and a beta of 0.64. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $4.18. The stock’s 50-day moving average is $1.26 and its 200 day moving average is $1.14.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds have recently made changes to their positions in the business. Bridgeway Capital Management LLC increased its stake in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares during the period. Bank of America Corp DE increased its stake in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the period. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $48,000. Finally, Marshall Wace LLP purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $113,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.